Results 1 to 10 of about 85,599,609 (253)

The effects of DPP-4 inhibitor on hypoxia-induced apoptosis in human umbilical vein endothelial cells

Journal of Pharmacological Sciences, 2017
Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of oral hypoglycemic agents for patients with type 2 diabetes mellitus and have potential antiatherosclerotic properties.
Akari Nagamine, Hiroshi Hasegawa, Naoko Hashimoto, Tomoko Yamada-Inagawa, Masanori Hirose, Yuka Kobara, Hiroyuki Tadokoro, Yoshio Kobayashi, Hiroyuki Takano   +8 more
doaj   +2 more sources

A DPP-4 inhibitor suppresses fibrosis and inflammation on experimental autoimmune myocarditis in mice. [PDF]

PLoS ONE, 2015
Myocarditis is a critical inflammatory disorder which causes life-threatening conditions. No specific or effective treatment has been established. DPP-4 inhibitors have salutary effects not only on type 2 diabetes but also on certain cardiovascular ...
Hiroyuki Hirakawa, Hirofumi Zempo, Masahito Ogawa, Ryo Watanabe, Jun-Ichi Suzuki, Hiroshi Akazawa, Issei Komuro, Mitsuaki Isobe   +7 more
doaj   +2 more sources

DPP-4 inhibitor attenuates toxic effects of indoxyl sulfate on kidney tubular cells. [PDF]

PLoS ONE, 2014
Diabetic nephropathy is a common causative factor of chronic kidney disease (CKD). DPP-4 inhibitor has the ability to improve kidney function and renal microvasculature.
Wei-Jie Wang, Chen-Hung Chang, Mao-Feng Sun, Sheng-Feng Hsu, Ching-Sung Weng   +4 more
doaj   +2 more sources

A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes

Lipids in Health and Disease, 2017
Background Previous studies suggest that dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium glucose cotransporter 2 (SGLT2) inhibitors have different effects on the lipid profile in patients with type 2 diabetes.
Seon-Ah Cha, Yong-Moon Park, Jae-Seung Yun, Tae-Seok Lim, Ki-Ho Song, Ki-Dong Yoo, Yu-Bae Ahn, Seung-Hyun Ko   +7 more
doaj   +2 more sources

Protective effects of DPP-4 inhibitor on podocyte injury in glomerular diseases [PDF]

BMC Nephrology, 2020
Background Dipeptidyl peptidase-4 (DPP-4) is a serine protease that inhibits the degradation of glucagon-like peptide 1. DPP-4 inhibitors are used worldwide to treat type 2 diabetes mellitus and were recently shown to have pleiotropic effects such as ...
Ayano Kubo, Teruo Hidaka, Maiko Nakayama, Yu Sasaki, Miyuki Takagi, Hitoshi Suzuki, Yusuke Suzuki   +6 more
doaj   +2 more sources

A dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, attenuates cardiac dysfunction after myocardial infarction independently of DPP-4

Journal of Pharmacological Sciences, 2019
Dipeptidyl peptidase-4 (DPP-4) inhibitors not only improve impaired glucose tolerance in diabetes, but also have pleiotropic extra-pancreatic effects such as preconditioning effect for myocardial ischemia-reperfusion injury.
Takehiro Yamaguchi, Ayano Watanabe, Masako Tanaka, Masayuki Shiota, Mayuko Osada-Oka, Soichi Sano, Minoru Yoshiyama, Katsuyuki Miura, Shojiro Kitajima, Shinji Matsunaga, Shuhei Tomita, Hiroshi Iwao, Yasukatsu Izumi   +12 more
doaj   +2 more sources

Inadequate Triglyceride Management Worsens the Durability of Dipeptidyl Peptidase-4 Inhibitor in Subjects with Type 2 Diabetes Mellitus [PDF]

Journal of Diabetes Research, 2017
Dipeptidyl peptidase-4 (DPP-4) inhibitors are often used all over the world and exert various beneficial effects including glucose-lowering effect in many subjects with type 2 diabetes.
Masashi Shimoda, Maiko Miyoshi-Takai, Shintaro Irie, Akihito Tanabe, Atsushi Obata, Seizo Okauchi, Hidenori Hirukawa, Tomohiko Kimura, Kenji Kohara, Shinji Kamei, Tomoatsu Mune, Kohei Kaku, Hideaki Kaneto   +12 more
doaj   +2 more sources

DPP-4 inhibition protects human umbilical vein endothelial cells from hypoxia-induced vascular barrier impairment

Journal of Pharmacological Sciences, 2017
Dipeptidyl peptidase-4 (DPP-4) inhibitors are relatively new class of anti-diabetic drugs. Some protective effects of DPP-4 on cardiovascular disease have been described independently from glucose-lowering effect.
Naoko Hashimoto, Kento Ikuma, Yui Konno, Masanori Hirose, Hiroyuki Tadokoro, Hiroshi Hasegawa, Yoshio Kobayashi, Hiroyuki Takano   +7 more
doaj   +2 more sources

DPP-4 inhibitor anagliptin protects against hypoxia-induced cytotoxicity in cardiac H9C2 cells

Artificial Cells, Nanomedicine, and Biotechnology, 2019
Cardiovascular complications are the leading cause of mortality and morbidity in type 2 diabetes patients. Diabetes greatly increases the risk of heart disease; therefore, the management of diabetes often involves the prevention of heart disease.
Yunxiang Ma, Junkai Wang, Changhua Wang, Qiong Zhang, Yannan Xu, Huajin Liu, Xia Xiang, Jiangwei Ma   +7 more
doaj   +2 more sources

4-Hydroxyisoleucine as a Natural DPP-4 Inhibitor for Diabetes [PDF]

Biology, Medicine & Natural Product Chemistry
Research on 4-hydroxyisoleucine, a natural compound found in several plant sources, shows potential as an antidiabetic agent through inhibiting the DPP-4 (dipeptidyl peptidase-4) enzyme.
Amir Thalib, Irma Putri Damayanti
doaj   +2 more sources